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Abstract
Objective: This systematic review evaluated the efficacy of immunobiologics for the 
management of oral disease in Sjögren's syndrome (SS).
Materials and Methods: MEDLINE®, Embase, Scopus, and the Cochrane Library were 
searched for evidence on the use of immunobiologics for management of glandular 
disease in SS. Primary outcomes were xerostomia and salivary gland dysfunction, as-
sessed via visual analogue scales, disease- specific scales for SS, measurement of sali-
vary flow, ultrasound data, and quality of life measures.
Results: Seventeen studies (11 randomized controlled trials and 6 observational stud-
ies) met inclusion criteria. Rituximab showed efficacy in improving salivary gland 
function but not xerostomia. Abatacept showed promise in improving both xerosto-
mia and salivary flow. Belimumab exhibited long- term improvement of salivary flow 
and subjective measures. The novel agent CFZ533 improved both disease activity 
and patient- reported indexes.
Conclusions: There is strong evidence pointing to the efficacy of rituximab in the 
management of oral disease in SS. Future controlled trials may elucidate the efficacy 
of belimumab and abatacept. The new drug CFZ533 is a promising alternative for the 
management of SS and its salivary gland involvement. In considering these agents, 
the promise of efficacy must be balanced against the harmful effects associated with 
biologic agents.
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1  | INTRODUCTION
Sjögren's syndrome (SS) is an autoimmune disease affecting approx-
imately 3.1 million patients in the United States of America (Carsons 
et al., 2017). The disease is chronic and often slowly progressive. 
Early impact occurs in the secretory glands, predominantly the sal-
ivary and lacrimal glands. However, SS can also affect the joints, 
gastrointestinal tract, central nervous system, and other organs, and 
has been linked to an increased risk for lymphoma (Alunno, Leone, 
Giacomelli, Gerli, & Carubbi, 2018). The majority of affected pa-
tients are diagnosed with SS in the absence of other autoimmune 
conditions (primary SS—pSS). Some patients, however, may develop 
secondary SS (sSS) as a sequela of rheumatological conditions in-
cluding systemic lupus erythematosus and rheumatoid arthritis 
(Georgakopoulou, Andreadis, Arvanitidis, & Loumou, 2013).
In the oral cavity, SS causes hyposalivation, manifesting as xe-
rostomia, by decreasing saliva production from the major salivary 
glands. Diminished salivary flow decreases patients’ functional 
ability and increases caries rate (von Bultzingslowen et al., 2007). 
Decreased salivary flow also has a profound negative impact on 
quality of life and can cause social isolation, depression, and lack of 
personal satisfaction. Control of these symptoms can be very chal-
lenging (Shiboski et al., 2017; Vivino et al., 2016).
The physical symptoms of SS are treated with a variety of medi-
cations, ranging from topical salivary substitutes to systemic agents. 
Many patients with primarily oral manifestations of SS are managed 
with cholinergic agents such as pilocarpine or cevimeline, both of 
which have been found to increase the flow of saliva and improve 
the patient experience of oral dryness. In addition, some patients are 
managed with disease- modifying antirheumatic drugs (DMARDs) in-
cluding azathioprine, hydroxychloroquine, and cyclosporine. Studies 
focused on these agents have shown mixed results when compared 
with placebo. The management of SS with non- pharmaceutical ther-
apies has also been investigated, with potential benefit found after 
use of acupuncture and electrostimulation (Al Hamad, Lodi, Porter, 
Fedele, & Mercadante, 2019).
A newer and less studied area in SS is the use of immunobiologics 
for treatment. Immunobiologics, or biologic agents, are defined by 
the National Cancer Institute at the United States’ National Institutes 
of Health as “a substance made from a living organism or its prod-
ucts and used in the prevention, diagnosis, or treatment of cancer and 
other diseases. Biologic agents include antibodies, interleukins, and 
vaccines” (National Cancer Institute, 2019). Since the first biologic 
agent was approved for patient treatment in 1998, this category of 
medications has significantly expanded in use and prevalence. A wide 
variety of agents that target distinct pathways are currently available.
A developing body of literature has investigated the use of bi-
ologic agents in the treatment of SS, particularly in patients with 
severe systemic complications (Sambataro, Sambataro, Dal Bosco, 
& Polosa, 2017). Existing literature has focused on the use of ritux-
imab, with a weak recommendation for the use of rituximab to treat 
sicca symptoms and moderate recommendation for use of rituximab 
to treat systemic disease (Letaief et al., 2018; Saraux, 2010; Souza, 
Porfirio, Andriolo, Albuquerque, & Trevisani, 2016; Verstappen, 
van Nimwegen, Vissink, Kroese, & Bootsma, 2017). The World 
Workshop on Oral Medicine VII reviewed the literature relating to 
the use of biologic agents on oral signs and symptoms in SS. Existing 
literature has not been combined into a consensus on the use of rit-
uximab for treatment of SS, particularly where oral signs and symp-
toms are concerned. In addition, limited evidence exists on use of 
other immunobiologics in SS. Given these points, we performed a 
systematic review with two objectives: (a) to determine the efficacy 
of rituximab as compared to placebo treatment for the treatment 
of oral disease related to pSS, as measured through symptomatic 
improvement and objective change in salivary measures and (b) to 
determine the evidence available for use of other biologic agents to 
treat the oral component of SS.
2  | METHODS
We searched the English language literature for studies and reviews in 
MEDLINE® (via PubMed), Embase, Scopus, and the Cochrane Library 
from date of database inception through October 25, 2018, using 
general terms for biologics, or terms for specific drugs or drug classes 
combined with terms for SS. We used either medical subject headings 
(MeSH) or Embase subject headings (Emtree) where available and 
keywords when applicable. We searched for conference papers in 
Embase and Scopus and unpublished clinical trials using ClinicalTrials.
gov and the WHO International Clinical Trials Registry Platform. This 
study was structured according to the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) statement.
Our literature search initially included case reports, case series, 
narrative reviews, observational studies, and randomized clinical 
trials (RCTs) where full text was available and any abstracts that 
contained sufficient data for analysis. For this systematic review, in-
clusion criteria were restricted to RCTs and observational studies, 
either in full text or abstract form, that discussed the use of biologic 
agents in SS and were published after January 1, 2002. No restric-
tions were imposed on the duration of follow- up. Exclusion criteria 
included papers not in English, where the full text was not available, 
and the abstract did not contain sufficient information, those that 
reported on interventions other than biologic agents, and papers 
that did not include sufficient information about oral outcomes.
Titles and abstracts of all references were screened by two in-
dependent reviewers (LAG and KF). Any disagreement was resolved 
K E Y WO RD S
biologic agents, salivary flow, Sjogren's syndrome, xerostomia
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through discussion and consensus. Full text of all potentially rele-
vant papers was reviewed and screened in duplicate. Discordances 
were resolved through discussion. Ineligible studies were sorted 
according to exclusion criteria. Relevant data from included arti-
cles was extracted into a standardized form by either LAG or KF 
and independently verified by the other. Information from each 
included study was then collected including but not limited to (a) 
participants—individuals diagnosed with SS according to American- 
European consensus group (AECG) (Vitali et al., 2002), American 
College of Rheumatology (ACR) (Shiboski et al., 2012) or ACR/
European League Against Rheumatism (EULAR) (Shiboski et al., 
2017) or other criteria, demographic details including age, gender, 
disease duration and severity, and indication for treatment with im-
munobiologics; (b) immunobiologic agent prescribed and any addi-
tional treatment; (c) dosage, frequency, route of administration, and 
number of doses; (d) control; (e) outcome measures; and (f) adverse 
events. Observational studies were considered when there was no 
evidence available from RCTs on a particular agent. Risk of bias for 
randomized controlled studies was assessed using the Cochrane 
Collaboration tool and included random sequence generation and 
selection, allocation concealment (selection bias), blinding of par-
ticipants and personnel (performance bias), blinding of outcome 
assessment in patient- related outcomes (detection bias), blinding 
of outcome assessment for mortality (detection bias), incomplete 
short- term (2–6 weeks) outcome data addressed (attrition bias), 
incomplete long- term (>6 weeks) outcome data addressed (attrition 
bias), and selective reporting (reporting bias) (Higgins et al., 2011). 
Risk of bias from observational studies was assessed and is included 
as Supporting Information Table S1.
The primary outcomes in this study were xerostomia and sali-
vary gland function as measured by unstimulated and stimulated 
salivary flow rates. Secondary outcomes included: visual analogue 
scales (VAS) for oral dryness, overall dryness, and global measures, 
the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) 
(Seror et al., 2010), symptomatic changes evaluated through the 
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) (Seror 
et al., 2011), and quality of life measures. A qualitative synthesis was 
planned to combine any outcome measures reported homogenously 
across included studies.
The level of evidence (LOE) was assessed according to the 
Somerfield criteria (Somerfield et al. 2000), which considers and 
scores the type of evidence from I (meta- analyses and well- designed 
RCTs) to V (case reports) and provides a grade for the recommenda-
tion (ranging from A to D based on the strength of the conclusions).
3  | RESULTS
We included 17 randomized controlled trials (RCTs) and obser-
vational studies in this review (Figure 1). Most of the included 
F IGURE  1 Flow chart of study 
selection according to the Preferred 
Reporting Items for Systematic Reviews 
and Meta- Analyses (PRISMA) standard
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studies diagnosed subjects according to AECG criteria (nine stud-
ies) (Vitali et al., 2002). Eleven RCTs were identified that reported 
on seven studies. Of these, four studied the use of rituximab, 
while one each studied infliximab, etanercept, and the novel agent 
CFZ533. Six papers reported on five observational studies using 
abatacept, epratuzumab, and belimumab. Observational studies 
covering agents evaluated in the included RCTs (11 papers on 
rituximab and 1 paper on etanercept) were not included in this 
report (Figure 1a).
In terms of outcomes, six studies measured xerostomia via a VAS. 
ESSPRI, which includes xerostomia, was examined in two studies. 
Salivary gland function was assessed using unstimulated salivary 
flow (n = 12 papers) and stimulated salivary flow (n = 4 papers). 
Studies also assessed objective measures using ESSDAI. Salivary 
gland morphology and volume, measured by ultrasonography, were 
evaluated in three studies. Most studies reported a low rate of side 
effects, and none reported any side effects specific to the oral cav-
ity. There was significant heterogeneity in how xerostomia and sal-
ivary gland- related outcomes were reported between the studies, 
preventing a metanalysis from being performed.
Risk of bias for the RCT reports is shown in Figure 2. Nine of 
the reports showed both adequate sequence generation and alloca-
tion concealment. Blinding of treatment was observed in 8 of 11 pa-
pers, but outcome assessors were clearly blinded in only one paper. 
Outcome data were complete in 7 of the manuscripts, and 8 of 11 
were free from selective reporting.
The majority of the included studies investigated the use of anti- 
B- cell agents (rituximab: four studies, belimumab and epratuzumab: 
one each), followed by anti- tumor necrosis factor (TNF) agents (in-
fliximab, etanercept: one each), costimulatory signal inhibitors (aba-
tacept: 3), and a novel anti CD40 inhibitor (CFZ533: 1). These studies 
are described below and summarized in Supporting Information 
Tables S2 and S3. A summary of the evidence from all included stud-
ies is described in table 1.
No deaths secondary to treatment with immunobiologics were 
reported by any included study. Although AEs were commonly ob-
served, they were often mild and self- limited. Infectious AEs were 
frequent, but severe infection was rarely observed. Cancer was a 
significant AE reported occurring in six patients (three cases of 
breast cancer). Oral AEs were rarely reported and included stoma-
titis (abatacept), aphthous- like lesions (belimumab), and dental ab-
scess (epratuzumab).
3.1 | Anti-­B-­cell­agents
3.1.1 | Rituximab
Rituximab is a chimeric monoclonal antibody that targets CD20 
on the surface of B cells and causes apoptosis. Rituximab use in 
Sjögren's syndrome was investigated in four RCTs and reported in 
eight manuscripts.
Dass et al. (2008) completed the first RCT on patients with pSS. 
Although the primary outcomes of this trial were global disease 
ratings, the authors did evaluate unstimulated salivary flow rate be-
fore and after treatment. Rituximab did not improve the unstimu-
lated salivary flow compared to placebo. This study was found to 
have a low to unclear risk of bias.
Meijer et al. (2010) evaluated both stimulated and unstimulated 
salivary flow rates, as well as oral dryness via VAS. They found a re-
duction in oral dryness ratings in the rituximab group. Oral dryness 
during the night showed a sustained response during follow- up for 
48 weeks. Rituximab promoted the improvement of both stimulated 
and unstimulated whole saliva, as well as salivary flow in both the 
parotid and submandibular/sublingual glands. In contrast, patients 
treated with placebo exhibited a reduction in salivary flow over the 
treatment period. Their study showed a low risk of bias in the ma-
jority of domains.
The Tolerance and Efficacy of Rituximab in Primary Sjögren's 
Syndrome (TEARS) study was reported on multiple studies. 
Devauchelle- Pensec et al. (2014) showed that after treatment with 
rituximab, oral VAS and salivary flow rate did not significantly improve. 
ESSDAI decreased, but this effect was only significant at week 6. This 
F IGURE  2 Risk of bias evaluation of randomized clinical trials 
according to Cochrane Collaboration risk of bias tool
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report was at low risk of bias. Jousse- Joulin et al. (2015) evaluated ul-
trasonographic findings in these patients and reported a reduction in 
salivary gland swelling during treatment. In this report, both outcome 
data and reporting measures were found to be at high risk of bias. 
Cornec et al. (2016) also evaluated ultrasonographic findings and re-
ported a decrease in hypoechoic areas in those patients who reported 
at least a 30% improvement in oral dryness (responders). In addition, 
rituximab responders had higher baseline unstimulated whole salivary 
flow rates (more mild disease) than non- responders. In this study, only 
attrition exhibited high risk of bias. Cornec et al. (2017) correlated 
quality of life measures as determined by the Short Form 36 (SF- 36) 
with ratings of SS disease activity. They found that patient ESSPRI rat-
ings, measuring subjective symptoms, were strongly correlated with 
SF- 36, with significant correlations between ESSPRI rating and each 
individual domain of the SF- 36. The ESSDAI ratings did not correlate 
with the overall SF- 36 score or with the majority of reported domains. 
This study showed a low overall risk of bias.
Finally, the TRial of Anti- B- Cell Therapy In patients with primary 
SS (TRACTISS) study was reported in two publications (Bowman 
et al., 2017; Fisher et al., 2018). Bowman et al. (2017) reported no 
difference between rituximab and placebo in the number of pa-
tients with at least a 30% reduction in their ratings of fatigue and 
oral dryness. The mean unstimulated salivary flow difference be-
tween groups was, however, statistically significant. Fisher et al. 
(2018) evaluated salivary gland ultrasounds at baseline and at least 
once after that. They scored improvement as Total Ultrasound Score 
(TUS), a combined measure of echogenicity, consistency, definition, 
glands involved, and size of hypoechoic foci. TUS reduction at weeks 
16 and 48 was significant and stable over time. The glandular char-
acteristics displayed statistically significant improvement at week 16 
and continued improvement at week 48. TUS alteration was not as-
sociated with ESSDAI or salivary flow rates at any time points. Both 
of these studies showed a low risk of bias.
These results show mixed evidence for the use of rituximab in SS, 
with a combined LOE of IB (LOE IB).
3.1.2 | Epratuzumab
There was one observational study on Epratuzumab. This is a human 
monoclonal antibody that targets the CD22 protein on mature B 
cells. In their 2006 study, Steinfeld and colleagues investigated the 
use of epratuzumab in pSS (Steinfeld et al., 2006). Throughout the 
study period, successively larger percentages of patients exhibited 
subjective improvement as measured by at least 20% improvement 
in VAS for dry mouth over baseline (LOE IIIB).
3.1.3 | Belimumab
There was one observational study reported in two papers assess-
ing belimumab's efficacy for treatment of SS. Belimumab is a human 
monoclonal antibody targeting B- cell- activating factor (BAFF). 
Mariette et al. (2015) evaluated the efficacy of belimumab in pSS. 
They showed a significant reduction in VAS for dry mouth, ESSDAI, 
and ESSPRI. No change in salivary flow rate was observed. De Vita 
et al. (2015) also reported on this trial. They noted that those pa-
tients responding at week 28 maintained or improved their subjec-
tive and objective measures at week 52 (LOE: IIIB).
3.2 | Anti-­TNF
3.2.1 | Infliximab
Infliximab is a chimeric anti- TNF agent targeting TNF- α that was 
explored in the Trial of Remicade in Primary Sjögren's Syndrome 
(TRIPSS), an RCT. Mariette et al. (2004) published the results in 2004. 
There was no sustainable response to treatment and no significant 
TABLE  1 Summary of efficacy of the immunobiologics in the management of salivary gland disease of Sjögren's syndrome
Category of agent Medication Type of study Summary of evidence LOE
Anti- B cell Rituximab RCTs Improvement of unstimulated salivary flow rate, effect on 
xerostomia not demonstrated. 
Significant improvement in glandular parenchyma in two studies.
IB
Epratuzumab Single group open 
trial
Improvement in unstimulated flow (36% of patients at week 18 
and in 64% of patients at week 32).
IIIB
Belimumab Single group open 
trial
Reduction in VAS dryness, ESSPRI and ESSDAI, with evidence of 
sustained response (52 weeks). No improvement in salivary gland 
function. Reduction in non- malignant salivary gland swelling.
IIIB
Anti- TNF- α Infliximab RCT No difference in salivary flow rates or xerostomia. No changes in 
microscopic aspects of minor salivary glands.
IIB
Etanercept RCT No difference in VAS dryness. No improvement in salivary gland 
function.
IIB
Costimulatory 
Signal Inhibitors
Abatacept Single group open 
trials
Two of three papers demonstrated improvement in salivary gland 
function. Reduction of ESSPRI and ESSDAI was observed until 
24 weeks but not after 48 weeks. Improvement of xerostomia 
was noted.
IIIB
Anti- CD40 CFZ533 RCT ESSPRI and ESSDAI improved with the higher dose (10 mg/kg). IIB
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difference between groups in VAS. There was no significant change 
in focus score or salivary flow rate after treatment. This study was at 
low risk of bias except as related to funding sources (LOE: IIB).
3.2.2 | Etanercept
Etanercept is a fusion protein that binds to TNF- α. Sankar et al. 
(2004) completed an RCT to evaluate its efficacy in SS and failed 
to show evidence of improvement in any oral or general outcomes. 
This trial did show high risk of bias in both attrition and reporting and 
uncertain risk in multiple other domains (LOE IIB).
3.3 | Costimulatory­signal­inhibitors
3.3.1 | Abatacept
There were three observational studies assessing abatacept effi-
cacy in SS. Abatacept is a fusion protein that targets CD80 and 
CD86 on T cells, preventing activation. Adler et al. (2013) studied 
the histologic, serologic, and clinical response of 11 pSS patients to 
abatacept. The authors observed a significant increase in saliva se-
cretion, a reduction in focus scores on minor salivary gland biopsy, 
and a decreased density of infiltrating lymphocytes within the foci 
after treatment.
Meiners et al. (2014) evaluated the efficacy of abatacept in 15 
patients with early and active pSS. Patients were required to ex-
hibit a stimulated whole salivary flow rate higher than 0.1 mL/min 
for inclusion. Median ESSDAI decreased at week 24 but returned 
to baseline by week 48. ESSPRI decreased during treatment and did 
not rebound. Unstimulated salivary flow did not change during or 
after treatment, while stimulated salivary flow was stable during 
treatment and decreased significantly post- treatment.
Tsuboi et al. (2016) evaluated the efficacy of abatacept in pa-
tients with SS and rheumatoid arthritis (sSS) using salivary gland 
biopsy and salivary flow rate. Patients with a less notable minor sal-
ivary gland inflammatory infiltrate at baseline exhibited an increase 
in salivary flow rate at week 24.
These combined results show a trend toward increased salivary 
flow and improved subjective measures after treatment with abata-
cept (LOE IIIB).
3.4 | Anti-­CD40
3.4.1 | CFZ533
CFZ533 is a potent inhibitor of CD40 stimulation, limiting the forma-
tion of ectopic germinal centers. Fisher et al. (2017) performed an 
RCT to evaluate the effect of either 3 mg/kg or 10 mg/kg CFZ533 
in four doses over 3 weeks for pSS. The higher dose was shown to 
reduce the ESSDAI most effectively. ESSPRI and serum levels of 
CXCL13 (a germinal center- related biomarker) were also reduced 
(LOE: IIB). This study is currently only published in abstract form, 
leaving most categories at uncertain risk of bias.
4  | DISCUSSION
Immunobiologics have been clinically tested and used in the off- label 
management of SS and its systemic complications for more than a 
decade (Zandbelt et al., 2004). Some systematic reviews have as-
sessed the use of these drugs in the management of systemic dis-
ease in SS (Al Hamad et al., 2019; Souza et al., 2016), but this is the 
first systematic review to assess the efficacy of immunobiologics in 
the management of oral disease. We determined efficacy by con-
sidering several outcomes including salivary flow, xerostomia, and 
ultrasonographic pattern of major salivary glands. Eleven RCTs and 
18 observational studies were included, reporting on four classes of 
biologics—anti- B cell (rituximab, epratuzumab, and belimumab), anti- 
TNF (infliximab and etanercept), inhibition of costimulatory signal 
(abatacept), and anti- CD40 (CFZ533) therapy. RCTs included 477 
patients (253 on biologics) and observational studies included 127 
patients on biologics. Oral outcomes were clearly described in each 
study. Overall, these studies showed a very low rate of adverse ef-
fects, but recognized complications from the use of biologic agents 
should be thoroughly discussed with patients before treatment with 
these drugs. Rituximab has been evaluated most extensively, allow-
ing for more conclusions on this agent.
Our results clearly show, based on two RCTs, that infliximab and 
etanercept are ineffective for the management of salivary gland dis-
ease in SS (Mariette et al., 2004; Sankar et al., 2004). Treatment with 
these medications produced no difference in oral dryness or salivary 
flow.
On the other hand, abatacept, an agent that prevents the antigen- 
presenting cells from delivering the costimulatory signal, showed 
promise in three open- label studies (Adler et al., 2013; Meijer et al., 
2010; Tsuboi et al., 2016). In these studies, improvements to xero-
stomia and salivary flow rates (both unstimulated and stimulated) 
were observed, as was as a reduction in the inflammatory infiltrate in 
minor salivary glands. Since these studies had an open- label design, 
however, RCTs are required to confirm these findings.
Anti- B- cell treatment has been most commonly used to reduce 
SS disease activity and manage systemic complications. However, 
studies on rituximab show mixed evidence on the agent's efficacy 
for treating oral disease in SS. The RCTs studying rituximab were 
mostly at low risk of bias, with some areas of each exhibiting un-
clear risk of bias, and with selected domains at high risk of bias in 
two studies (Cornec et al., 2016; Jousse- Joulin et al., 2015). The 
TEARS and TRACTISS studies have demonstrated that rituximab 
was able to improve salivary gland echostructure by modifying 
glandular patterns after treatment (Fisher et al., 2018; Jousse- 
Joulin et al., 2015). On the other hand, there are conflicting data 
regarding its efficacy on xerostomia and salivary flow. Meijer et al. 
(2010) reported benefit from rituximab in the improvement of oral 
dryness. They included patients with residual stimulated salivary 
flow at baseline, which may be the key to a clinically relevant re-
sponse. As part of the TEARS study, Cornec et al. (2016) evaluated 
those patients who had salivary gland ultrasound data available at 
baseline and also reported an improvement of xerostomia. They 
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showed that patients who presented at least 30% improvement in 
oral dryness VAS had fewer salivary gland ultrasound alterations 
at baseline, reinforcing the hypothesis that a measurable sali-
vary gland function at baseline is important to clinical response. 
However, the analysis of the entire TEARS cohort showed a sta-
ble, but non- significant reduction in oral dryness after rituximab 
treatment (Devauchelle- Pensec et al., 2014). Bowman et al. (2017) 
also failed to show changes in oral dryness at any time point in the 
TRACTISS study. Their inclusion of patients with severe glandular 
disease may have influenced this outcome.
The effect of rituximab on xerostomia was also evaluated in 
seven observational studies, each of which showed a positive ef-
fect (Carubbi et al., 2013; Devauchelle- Pensec et al., 2011, 2007; 
Galarza et al., 2008; Gottenberg et al., 2005; Pijpe et al., 2005; St 
Clair et al., 2013), although the uncontrolled nature of these stud-
ies may have influenced the results (Concato, Shah, & Horwitz, 
2000). These data also showed improvement of parotid gland 
swelling in small numbers of affected patients (Galarza et al., 2008; 
Gottenberg et al., 2005, 2013). In addition, not all studies com-
mented on the timing of treatment or salivary gland function at 
baseline of included subjects, which may explain some variation in 
the reported results.
Our results, therefore, suggest that rituximab is effective in 
improving the salivary flow rate in SS. Meijer et al. (2010) and the 
TRACTISS study (Bowman et al., 2017) each reported improvement, 
while the TEARS study (Devauchelle- Pensec et al., 2014) showed no 
change in flow. However, the TEARS study included patients up to 
10 years after initial diagnosis, and patients received two doses of 
rituximab on weeks 0 and 2 postenrollment. In contrast, Meijer et al. 
(2010) evaluated patients with at least some residual saliva (stimu-
lated whole saliva ≥ 0.15 ml/minute). The TRACTISS study was pri-
marily designed to evaluate the effect of rituximab on oral dryness 
and four doses were administered at weeks 0, 2, 24, and 26 posten-
rollment. These additional doses, along with a measurable baseline 
salivary flow, may be responsible for the sustained improvement.
Other anti- B- cell therapies have also shown some benefit in the 
management of oral disease in SS. Preliminary results on the use of 
belimumab from one uncontrolled trial suggest some efficacy as 
measured by xerostomia, parotid gland swelling, and ESSDAI. The 
results were particularly promising for the glandular domain of this 
scale. However, no effect on salivary flow was observed (De Vita 
et al., 2015; Mariette et al., 2015).
Epratuzumab is an anti- CD22 drug that causes less B- cell de-
pletion than rituximab, and its use in SS patients showed a clini-
cally significant improvement of salivary flow in more than 60% 
of the patients studied in one observational trial (Steinfeld et al., 
2006).
Recently, a new intervention was proposed to treat SS. CFZ533, 
a drug that selectively blocks CD40 costimulation and reduces ger-
minal center formation, was tested in an RCT in 3 mg/kg and 10 mg/
kg doses. This trial showed that the drug was safe and well toler-
ated, and the higher dose was more effective in reducing ESSDAI 
and ESSPRI (Fisher et al., 2017).
In summary, the use of biologics in SS represents a new fron-
tier in the management of this disease. Anti- B- cell therapies are 
the leaders of immunobiologics for treatment of SS. Here, we show 
that rituximab has the most evidence in the treatment of xerosto-
mia and stimulation of salivary flow improvement in SS, especially 
with continuous treatment. Abatacept, belimumab, epratuzumab, 
and CFZ533 are promising alternatives, and additional head- to- head 
RCTs may clarify their benefit and define cost- effectiveness.
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